Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease

Scandinavian Journal of Gastroenterology

Volumn 49, Issue 8, 2014, Pages 979-985

  Suh, Jun Bin ^a   Kim, Seon Mee ^a   Cho, Geum Ju ^a   Choi, Kyung Mook ^b  

^a Korea University College of Medicine   (South Korea)

^b Korea University   (South Korea)

Author keywords

Adipocyte fatty acid binding protein; Metabolic syndrome; Nonalcoholic fatty liver disease

Indexed keywords

FATTY ACID BINDING PROTEIN 4; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RETINOL BINDING PROTEIN 4; TRIACYLGLYCEROL; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; FABP4 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN; PLASMA RETINOL BINDING PROTEIN; RBP4 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; FATTY LIVER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; BLOOD; BODY HEIGHT; BODY WEIGHT; COMPLICATION; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

ACUTE-PHASE PROTEINS; ADULT; BIOLOGICAL MARKERS; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; FATTY ACID-BINDING PROTEINS; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOCALINS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS; RETINOL-BINDING PROTEINS, PLASMA; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TRIGLYCERIDES; WAIST CIRCUMFERENCE;

EID: 84904419183     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.836754     Document Type: Article

References (30)

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes 2001;50:1844-50. (Pubitemid 33641605)
2. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005;48:634-42. (Pubitemid 40591217)
3. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, et al. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002;87:3023-8. (Pubitemid 34816338)
4. Saltiel AR. Series introduction: The molecular and physiological basis of insulin resistance: Emerging implications for metabolic and cardiovascular diseases. J Clin Invest 2000; 106:163-4. (Pubitemid 30483116)
5. Hotamisligil GS. Role of endoplasmic reticulum stress and c-Jun NH2-terminal kinase pathways in inflammation and origin of obesity and diabetes. Diabetes 2005;54:S73-8. (Pubitemid 43343334)
6. Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals 2006;19:211-15. (Pubitemid 43794830)
7. Makowski L, Hotamisligil GS. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 2005;16:543-8. (Pubitemid 41376904)
8. Xu A, Tso AW, Cheung BM, Wang Y, Wat NM, Fong CH, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: A 5-year prospective study. Circulation 2007; 115:1537-43. (Pubitemid 46648638)
9. Choi KM, Yannakoulia M, Park MS, Cho GJ, Kim JH, Lee SH, et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: A 3-y prospective cohort study. Am J Clin Nutr 2011;93:19-26.
10. Tso AW, Xu A, Sham PC, Wat NM, Wang Y, Fong CH, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: A 10-year prospective study in a Chinese cohort. Diabetes Care 2007;30:2667-72. (Pubitemid 47547818)
11. Milner KL, van der Poorten D, Xu A, Bugianesi E, Kench JG, LamKS, et al.Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (Baltimore,Md) 2009;49:1926-34.
12. Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62. (Pubitemid 41065039)
13. Lee DC, Lee JW, ImJA. Association of serum retinol binding protein 4 and insulin resistance in apparently healthy adolescents. Metabolism 2007;56:327-31.
14. Seo JA, Kim NH, Park SY, Kim HY, Ryu OH, Lee KW, et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf) 2008;68:555-60. (Pubitemid 351388698)
15. Wang Y, Lam KS, Kraegen EW, Sweeney G, Zhang J, Tso AW, et al. Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans. Clin Chem 2007;53:34-41. (Pubitemid 46047761)
16. van Dam RM, Hu FB. Lipocalins and insulin resistance: Etiological role of retinol-binding protein 4 and lipocalin-2? Clin Chem 2007;53:5-7. (Pubitemid 46047757)
17. Choi KM, Lee JS, Kim EJ, Baik SH, Seo HS, Choi DS, et al. Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease. Eur J endocrinol 2008;158:203-7. (Pubitemid 351298537)
18. Marignani M, Angeletti S. Nonalcoholic fatty liver disease. N Engl J Med 2002;347:768-9; author reply -9.
19. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006;52:405-13.
20. Shen WJ, Sridhar K, Bernlohr DA, Kraemer FB. Interaction of rat hormone-sensitive lipase with adipocyte lipid-binding protein. Proc Natl Acad Sci USA 1999;96:5528-32. (Pubitemid 29234651)
21. Scheja L, Makowski L, Uysal KT, Wiesbrock SM, Shimshek DR, Meyers DS, et al. Altered insulin secretion associated with reduced lipolytic efficiency in aP2-/-mice. Diabetes 1999;48:1987-94. (Pubitemid 29458361)
22. Coe NR, Simpson MA, Bernlohr DA. Targeted disruption of the adipocyte lipid-binding protein (aP2 protein) gene impairs fat cell lipolysis and increases cellular fatty acid levels. J Lipid Res 1999;40:967-72. (Pubitemid 29220539)
23. Makowski L, Hotamisligil GS. Fatty acid binding proteins-The evolutionary crossroads of inflammatory and metabolic responses. J Nutr 2004;134:2464s-8s. (Pubitemid 39201622)
24. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nature reviews Drug discovery 2008;7:489-503. (Pubitemid 351767117)
25. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF, et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004;110:1492-8. (Pubitemid 39238029)
26. Cho YM, Youn BS, Lee H, Lee N, Min SS, Kwak SH, et al. Plasma retinol-binding protein-4 concentrations are elevated in human subjects with impaired glucose tolerance and type 2 diabetes. Diabetes Care 2006;29:2457-61. (Pubitemid 44912252)
27. Janke J, Engeli S, Boschmann M, Adams F, Bohnke J, Luft FC, et al. Retinol-binding protein 4 in human obesity. Diabetes 2006;55:2805-10. (Pubitemid 44923680)
28. Shin MJ, Kang SM, Jang Y, Lee JH, Oh J, Chung JH, et al. Serum retinol binding protein 4 levels are associated with serum adiponectin levels in non-diabetic, non-obese subjects with hypercholesterolemia. Clin Chim Acta 2007; 378:227-9. (Pubitemid 46241082)
29. Alkhouri N, Lopez R, Berk M, Feldstein AE. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009;43:985-9.
30. Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? Eur J Gastroenterol Hepatol 2003;15: 539-43. (Pubitemid 36571048)